Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) was the recipient of a significant increase in short interest during the month of January. As of January 12th, there was short interest totalling 1,864,347 shares, an increase of 75.6% from the December 29th total of 1,061,456 shares. Based on an average daily volume of 1,398,444 shares, the short-interest ratio is currently 1.3 days. Currently, 6.1% of the shares of the company are short sold.
A hedge fund recently raised its stake in Hemispherx BioPharma stock. Vanguard Group Inc. grew its holdings in Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) by 0.6% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 453,805 shares of the specialty pharmaceutical company’s stock after acquiring an additional 2,709 shares during the quarter. Vanguard Group Inc. owned 1.56% of Hemispherx BioPharma worth $227,000 as of its most recent SEC filing.
Hemispherx BioPharma (NYSEAMERICAN:HEB) traded up $0.04 during trading hours on Wednesday, hitting $0.59. 794,219 shares of the company’s stock traded hands, compared to its average volume of 1,494,707. Hemispherx BioPharma has a 12-month low of $0.30 and a 12-month high of $0.84. The firm has a market capitalization of $15.66, a P/E ratio of -2.11 and a beta of -0.94.
About Hemispherx BioPharma
Hemispherx Biopharma, Inc (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon.
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.